(688068)"BEIJING HOTGEN BIOTECH CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688068 · · 13 pages · Chinese
Beijing Hotgen Biotech Co. Ltd. on 6ix
Earlier from Beijing Hotgen Biotech
- (688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase II Clinical Study of the Subsidiary's SGC001 Innovative Drug for Indication of "Predicted Severe Acute Pancreatitis"
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase I/IIa Clinical Trial of Subsidiary's Innovative Drug SGT003
- Announcement on Change of Registered Capital, Amendment to the Articles of Association and Filing of Industrial and Commercial Registration Changes
- Announcement on Implementation Results of Share Repurchase and Share Changes
Later from Beijing Hotgen Biotech
- (688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Progress of Sale of Repurchased Shares
- (688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Poster Presentation of Phase Ib Clinical Data of the Subsidiary's SGC001 Innovative Drug at the American Heart Association (AHA) Scientific Sessions
Follow Beijing Hotgen Biotech into a list and get an email when it puts out news.
Follow Beijing Hotgen Biotech